Metabolism Disorder TRIZ Cases

Perinatal cell therapy suppresses autoimmune beta-cell destruction while improving insulin sensitivity and supporting long-term glucose control.

Stable genomic integration helps lentiviral LDLR vectors maintain liver expression through cell division during liver growth.

Critical-window mRNA transfection directs stem cells into glucose-sensing, insulin-secreting beta cells while reducing growth-factor and animal-product reliance.

Absorption enhancers help oral protein compositions cross the intestinal mucosal barrier while protease inhibitors preserve activity.

Potassium phosphate dibasic boluses dissolve rapidly in the rumen, delivering potassium and phosphorus while reducing risks linked to improper drenching.

Glucose-responsive microneedles release insulin in hyperglycemia and glucagon in low-glucose conditions, helping limit both hyperglycemic and hypoglycemic episodes.

Defined proportions of 18 herbal ingredients and cell-wall-breaking processing target reliable weight loss and lower blood lipids.

Elafibranor with an ACC inhibitor combines PPAR and fatty-acid-synthesis pathways to address inadequate multi-pathway outcomes.

LysB29 acylation slows insulin clearance to support at least 24-hour glucose control with improved stability.

Hexahydropentalene derivatives stabilize or destabilize LRH-1’s activation function surface to address limited treatment options.

Dual glycolytic and oxidative phosphorylation inhibition induces apoptosis and improves chemotherapy sensitivity in chemoresistant cancers.

Compound A targets thyroid hormone receptor beta to treat fatty liver while reducing effects on cardiovascular function and the hypothalamus/pituitary/thyroid axis.

Excess RBC cholesterol and low lipophilic antioxidants are addressed together through HDL enhancement to improve cell function and limit complications.

Ionization-stabilizing excipients keep therapeutic agents soluble and stable in aprotic polar solvents without drying.

Sulfonamide moieties bind serum albumin while insulin analog mutations reduce clearance, extending half-life without losing signal transduction.

Poor intestinal absorption limits peptide and protein medicines; potassium octanoate crystal forms improve solubility and stability for oral delivery.

Triple receptor activity combines glucose control and metabolic benefits with extended action, helping limit frequent dosing and gastrointestinal side effects.

High-affinity recombinant antibodies bind human IL-15 and its IL-15Rα complex, inhibit NK-cell proliferation, and reduce celiac inflammation.

Conservative CDR substitutions create anti-PD-1 antibody variants that target therapy resistance and support stronger immune responses in cancer treatment.

Dominant-negative SUN or KASH proteins uncouple cardiomyocyte nuclei from the cytoskeleton, reducing Sun1 cytotoxicity and DCM progression.

Asymmetric α-anordrin synthesis targets estrogen-deficiency symptoms with tissue-selective activity and lower cancer risk.

Electrodes in a swallowable capsule stimulate intestinal L-cells to release incretins for glucose and appetite regulation.